Literature DB >> 32713439

Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?

Kristin N Kelly1, Francisco I Macedo2, Nipun B Merchant3.   

Abstract

Entities:  

Keywords:  Borderline resectable pancreatic cancer; CA 19-9; FOLFIRINOX; Gemcitabine-abraxane; Locally advanced pancreatic cancer; Neoadjuvant chemotherapy; Portal vein resection; Whipple procedure

Year:  2020        PMID： 32713439     DOI： 10.1016/j.yasu.2020.05.001

Source DB:  PubMed          Journal:  Adv Surg        ISSN： 0065-3411


× No keyword cloud information.
  1 in total

1.  A Novel Four-Gene Score to Predict Pathologically Complete (R0) Resection and Survival in Pancreatic Cancer.

Authors:  Masanori Oshi; Yoshihisa Tokumaru; Ankit Patel; Li Yan; Ryusei Matsuyama; Itaru Endo; Matthew H G Katz; Kazuaki Takabe
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.